Product Pipeline for New Pharmaceutical Drugs
OUR MEDICINES IN DEVELOPMENT
Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients.
Key Innovative Programs
- Abrocitinib - JAK1 Inhibitor: Atopic Dermatitis
- Bavencio® (avelumab): Non-Small Cell Lung Cancer, Urothelial Cancer (in collaboration w/Merck KGaA)
- Braftovi® (encorafinib) + Mektovi® (binimetinib): BRAF-mutant metastatic Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer
- Duchenne Muscular Dystrophy Gene Therapy
- fidanacogene elaparvovec (Gene Therapy, coagulation factor IX): Hemophilia
- giroctocogene fitelparvovec (Gene Therapy, coagulation factor VIII): Hemophilia
- Next Generation Pneumococcal Conjugate Prophylactic Vaccine: Invasive and Non-Invasive Pneumococcal Infections
- Prophylactic Vaccine: Clostridioides difficile Infection
- Prophylactic Vaccine: Respiratory Syncytial Virus Infection (maternal)
- Ritlecitinib - JAK3/TEC Inhibitor: Alopecia Areata
- Talzenna® (talazoparib): Prostate Cancer
- Tanezumab: Chronic Pain due to Moderate-to-Severe Osteoarthritis, Cancer Pain
- Xeljanz® (tofacitinib): Ankylosing Spondylitis
- Xtandi® (enzalutamide): Metastatic Castration Sensitive Prostate Cancer, Non-Metastatic High-Risk Castration Sensitive Prostate Cancer
Pipeline Snapshot as of October 27, 2020
- Discovery Projects
- 29Phase 1
- 36Phase 2
- 21Phase 3
- 6Registration
- Total92
| Compound Name | Indication | Phase | Submission Type | Compound Type |
|---|---|---|---|---|
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Combo w/ Talzenna (talazoparib) and binimetinib for Solid Tumors (Biologic) | Phase 1 | Product Enhancement | Biologic |
danuglipron (PF-06882961) Therapeutic Area: Internal Medicine Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Glucagon-like peptide 1 receptor (GLP-1R) Agonist | Obesity | Phase 1 | Product Enhancement | Small Molecule |
PF-05082566 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: CD137 Agonist | Combo w/Kite Pharma'sYescarta (axicabtagene ciloleucel)forCancer | Phase 1 | New Molecular Entity | Biologic |
PF-06647020 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: protein tyrosine kinase 7 (PTK7) Targeted Cytotoxicity | Cancer (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06755347 Therapeutic Area: Rare Diseases Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: Immunomodulation | Chronic Inflammatory Demyelination Polyneuropathy | Phase 1 | New Molecular Entity | Biologic |
PF-06804103 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: HER2 Antibody Drug Conjugate | Cancer (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06821497 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: EZH2 inhibitor | Cancer | Phase 1 | New Molecular Entity | Small Molecule |
PF-06826647 Therapeutic Area: Inflammation & Immunology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: TYK2 Inhibitor | Ulcerative Colitis | Phase 1 | Product Enhancement | Small Molecule |
PF-06835375 Therapeutic Area: Inflammation & Immunology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: Chemokine Inhibitor | Lupus (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06842874 Therapeutic Area: Internal Medicine Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CDK 4,6 Inhibitor | Pulmonary Arterial Hypertension | Phase 1 | New Molecular Entity | Small Molecule |
PF-06863135 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: BCMA-CD3 Bispecific Antibody | Multiple Myeloma (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06873600 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CDK 2,4,6 inhibitor | Breast Cancer Metastatic | Phase 1 | New Molecular Entity | Small Molecule |
PF-06936308 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Therapeutic Vaccine | Multiple Cancers | Phase 1 | New Molecular Entity | Vaccine |
PF-06939926 Therapeutic Area: Rare Diseases Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: Gene Therapy, minidystrophin | Duchenne Muscular Dystrophy (Biologic) (FAST TRACK - U.S.; ORPHAN - U.S., E.U.) | Phase 1 | New Molecular Entity | Biologic |
PF-06939999 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: protein arginine methyltransferase 5 (PRMT5) Inhibitor | Solid Tumors | Phase 1 | New Molecular Entity | Small Molecule |
PF-06940434 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: Integrin alpha-V/beta-8 Antagonist | Solid Tumors (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06946860 Therapeutic Area: Internal Medicine Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: Growth Factor Blocker | Cachexia (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06952229 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: transforming growth factor, beta receptor 1 (TGFBR1) Inhibitor | Cancer | Phase 1 | New Molecular Entity | Small Molecule |
